This Pharmaceutical Stock Is Leading the S&P 500 Higher Tuesday, After 'Remarkable' Trial ResultsInvestopedia • 03/10/26
VRTX Stock Gains on Upbeat Interim Data From Kidney Disease Drug StudyZacks Investment Research • 03/10/26
Vertex Pharmaceuticals Incorporated (VRTX) Presents at Leerink Global Healthcare Conference 2026 TranscriptSeeking Alpha • 03/10/26
Vertex Pops On Positive Final-Phase Results For Chronic Kidney Disease DrugInvestors Business Daily • 03/09/26
Vertex Announces Positive Week 36 Interim Analysis Results for Primary and All Secondary Endpoints in the RAINIER Phase 3 Trial of Povetacicept in Adults With IgA NephropathyBusiness Wire • 03/09/26
Buying This 1 Biotech Stock Now Could Help Make You a Multimillionaire RetireeThe Motley Fool • 03/08/26
Vertex to Present New Data on JOURNAVX® That Demonstrates Effective Pain Management Following Aesthetic and Reconstructive ProceduresBusiness Wire • 03/05/26
Forget CRISPR Therapeutics: This Gene‑Editing Player Already Boasts the Profits It Dreams OfThe Motley Fool • 03/04/26
Vertex Pharmaceuticals Incorporated (VRTX) Presents at TD Cowen 46th Annual Health Care Conference TranscriptSeeking Alpha • 03/03/26
Forget Centessa Pharmaceuticals: This Rare‑Disease Specialist Has a Superior Portfolio and PipelineThe Motley Fool • 02/26/26
Vertex: The Quiet Biotech Compounder I'd Happily Hold Through Any Market CrashThe Motley Fool • 02/18/26
Vertex to Participate in TD Cowen 46th Annual Health Care Conference on March 3Business Wire • 02/17/26
VRTX's Q4 Earnings Miss Mark, Revenues Beat on Higher Product SalesZacks Investment Research • 02/13/26
Vertex (VRTX) Q4 Earnings: How Key Metrics Compare to Wall Street EstimatesZacks Investment Research • 02/13/26